« Back
Cesca Therapeutics Announces Registered Direct Offering
Cesca Therapeutics Announces Registered Direct Offering
March 26, 2018
The gross proceeds of this offering are expected to be approximately
The shares described above (but not the warrants or the shares underlying the warrants) are being offered pursuant to a “shelf” registration statement (File No. 333-212314) which became effective on
A prospectus supplement and accompanying base prospectus relating to the shares of common stock being offered will be filed with the
The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the shares of common stock issuable upon their exercise, have not been registered under the Act, and may not be offered or sold in
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About
Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Such forward-looking statements include, without limitation, statements with respect to the completion, timing and size of the offering and the expected proceeds from the offering. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics’ forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics’ annual report on Form 10-K, the transition report on Form 10-KT and other reports it files with the
Company Contact:
916-858-5191
ir@cescatherapeutics.com
Investor Contact:
917-322-2216
pschwartz@rxir.com
Source: Cesca Therapeutics Inc.